Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
262 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02131155 | LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy | terminated | Phase 3 | 36 | Boehringer IngelheimINDUSTRY | 4 | Mar 1, 2019 | clinicaltrials |
| NCT02483416 | Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance | terminated | — | 30 | Boehringer IngelheimINDUSTRY | 1 | Mar 1, 2019 | clinicaltrials |
| NCT00977431 | Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform | completed | Phase 1 | 36 | Boehringer IngelheimINDUSTRY | 1 | Feb 18, 2019 | clinicaltrials |
| NCT01523587 | LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy | completed | Phase 3 | 795 | Boehringer IngelheimINDUSTRY | 23 | Feb 15, 2019 | clinicaltrials |
| NCT01957644 | Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML | terminated | Phase 1 | 16 | Boehringer IngelheimINDUSTRY | 2 | Feb 8, 2019 | clinicaltrials |
| NCT01206816 | An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours | completed | Phase 1 | 57 | Boehringer IngelheimINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT00969761 | BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour | completed | Phase 1 | 61 | Boehringer IngelheimINDUSTRY | 1 | Jan 31, 2019 | clinicaltrials |
| NCT01145885 | BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours | completed | Phase 1 | 7 | Boehringer IngelheimINDUSTRY | 1 | Jan 31, 2019 | clinicaltrials |
| NCT02003573 | Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 13 | Boehringer IngelheimINDUSTRY | 1 | Jan 31, 2019 | clinicaltrials |
| NCT01938846 | BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 90 | Boehringer IngelheimINDUSTRY | 2 | Jan 4, 2019 | clinicaltrials |
| NCT01324830 | Monotherapy Dose Finding With BI 847325 in Solid Tumours | completed | Phase 1 | 69 | Boehringer IngelheimINDUSTRY | 1 | Dec 21, 2018 | clinicaltrials |
| NCT02208843 | Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation | completed | Phase 4 | 60 | Boehringer IngelheimINDUSTRY | 7 | Dec 17, 2018 | clinicaltrials |
| NCT01121393 | BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 364 | Boehringer IngelheimINDUSTRY | 3 | Dec 14, 2018 | clinicaltrials |
| NCT00805194 | LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer | completed | Phase 3 | 1,314 | Boehringer IngelheimINDUSTRY | 27 | Dec 5, 2018 | clinicaltrials |
| NCT01931306 | Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC) | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 14, 2018 | clinicaltrials |
| NCT02131259 | Long-term Observation PMS for Afatinib | completed | — | 1,605 | Boehringer IngelheimINDUSTRY | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01950273 | Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma | completed | Phase 1 | 95 | Boehringer IngelheimINDUSTRY | 13 | Sep 5, 2018 | clinicaltrials |
| NCT01348347 | BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours | completed | Phase 1 | 15 | Boehringer IngelheimINDUSTRY | 1 | Aug 6, 2018 | clinicaltrials |
| NCT01022853 | Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors | completed | Phase 1 | 30 | Boehringer IngelheimINDUSTRY | 1 | Jul 30, 2018 | clinicaltrials |
| NCT01662505 | Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 19 | Boehringer IngelheimINDUSTRY | 1 | Jul 30, 2018 | clinicaltrials |
| NCT01971476 | Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known | completed | Phase 1 | 22 | Boehringer IngelheimINDUSTRY | 5 | Jul 30, 2018 | clinicaltrials |
| NCT02201329 | Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | completed | Phase 1 | 5 | Boehringer IngelheimINDUSTRY | 1 | Jul 30, 2018 | clinicaltrials |
| NCT00949650 | BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | completed | Phase 3 | 345 | Boehringer IngelheimINDUSTRY | 25 | Apr 6, 2018 | clinicaltrials |
| NCT01345682 | LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy | completed | Phase 3 | 483 | Boehringer IngelheimINDUSTRY | 19 | Feb 15, 2018 | clinicaltrials |
| NCT03343678 | This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax | withdrawn | Phase 1 | 0 | Boehringer IngelheimINDUSTRY | 0 | Jan 9, 2018 | clinicaltrials |
| NCT00801294 | A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer | completed | Phase 2 | 46 | Boehringer IngelheimINDUSTRY | 1 | Dec 29, 2017 | clinicaltrials |
| NCT02182050 | Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer | completed | Phase 2 | 73 | Boehringer IngelheimINDUSTRY | 0 | Dec 28, 2017 | clinicaltrials |
| NCT02182063 | A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer | completed | Phase 2 | 81 | Boehringer IngelheimINDUSTRY | 0 | Dec 28, 2017 | clinicaltrials |
| NCT01015118 | LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer | completed | Phase 3 | 1,366 | Boehringer IngelheimINDUSTRY | 22 | Dec 7, 2017 | clinicaltrials |
| NCT01345669 | LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy | terminated | Phase 3 | 617 | Boehringer IngelheimINDUSTRY | 29 | Dec 7, 2017 | clinicaltrials |
| NCT01023958 | Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer | completed | Phase 2 | 50 | Boehringer IngelheimINDUSTRY | 2 | Nov 22, 2017 | clinicaltrials |
| NCT01004003 | Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 125 | Boehringer IngelheimINDUSTRY | 8 | Oct 26, 2017 | clinicaltrials |
| NCT02695290 | Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) | terminated | Phase 4 | 1 | Boehringer IngelheimINDUSTRY | 1 | Sep 18, 2017 | clinicaltrials |
| NCT00727506 | BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma | completed | Phase 2 | 151 | Boehringer IngelheimINDUSTRY | 2 | Aug 15, 2017 | clinicaltrials |
| NCT02149108 | Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) | completed | Phase 3 | 768 | Boehringer IngelheimINDUSTRY | 25 | Jul 21, 2017 | clinicaltrials |
| NCT02020577 | Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours | completed | Phase 1 | 58 | Boehringer IngelheimINDUSTRY | 2 | Jun 22, 2017 | clinicaltrials |
| NCT01085136 | LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib | completed | Phase 3 | 1,154 | Boehringer IngelheimINDUSTRY | 23 | Apr 4, 2017 | clinicaltrials |
| NCT02044380 | Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 3 | 14 | Boehringer IngelheimINDUSTRY | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00806819 | Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC | completed | Phase 3 | 718 | Boehringer IngelheimINDUSTRY | 32 | Feb 2, 2017 | clinicaltrials |
| NCT01647711 | A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations | completed | Phase 1 | 35 | Boehringer IngelheimINDUSTRY | 1 | Jan 31, 2017 | clinicaltrials |
| NCT02417129 | BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma | terminated | Phase 3 | 2 | Boehringer IngelheimINDUSTRY | 6 | Jan 30, 2017 | clinicaltrials |
| NCT01649284 | Afatinib Expanded Access Program | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 30, 2016 | clinicaltrials |
| NCT00876460 | BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I | completed | Phase 1 | 43 | Boehringer IngelheimINDUSTRY | 1 | Nov 17, 2016 | clinicaltrials |
| NCT01209650 | LUX Lung Special Access Scheme Australia Named Patient Use (NPU) | approved for marketing | — | — | Boehringer IngelheimINDUSTRY | 1 | Nov 10, 2016 | clinicaltrials |
| NCT01814553 | ADAM-Afatinib Diarrhea Assessment and Management | completed | Phase 3 | 40 | Boehringer IngelheimINDUSTRY | 1 | Oct 31, 2016 | clinicaltrials |
| NCT00824408 | Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC | completed | Phase 2 | 143 | Boehringer IngelheimINDUSTRY | 2 | Sep 20, 2016 | clinicaltrials |
| NCT00525148 | LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations | completed | Phase 2 | 129 | Boehringer IngelheimINDUSTRY | 2 | Sep 16, 2016 | clinicaltrials |
| NCT00710762 | A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer | completed | Phase 2 | 89 | Boehringer IngelheimINDUSTRY | 1 | Aug 15, 2016 | clinicaltrials |
| NCT00514943 | BIBW 2992 (Afatinib) in Head & Neck Cancer | completed | Phase 2 | 124 | Boehringer IngelheimINDUSTRY | 4 | Jul 26, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials